Savara Pharmaceuticals Inc. CEO Rob Neville told BioWorld Today the all-stock buyout of Serendex Pharmaceuticals A/S brings aboard a pair of orphan products, one of them "already enrolling phase II/III" trials in Europe and Japan for pulmonary alveolar proteinosis (PAP). "Being able to pull off an acquisition of a company like Serendex for a private company like us was a big win," he said.